Diabetes mellitus (DM) is the 4th leading cause of mortality in Taiwan. Chronic persistent inflammation as demonstrated by higher proinflammatory mediators in blood has been correlated to cardiovascular complications of type 2 DM. The cellular and molecular mechanism of chronic inflammation in type 2 DM remains to be determined. This study was conducted to explore altered innate immunity in toll-like receptor (TLR) expression and signaling of monocytes from type 2 DM patients. Blood leukocytes from type 2 DM patients were counted and studied for TLR2 and TLR4 expression and signaling. Each experiment was run with 1 to 2 type 2 DM patients, simultaneously with 1 to 2 age-matched normal adults as controls. 31 type 2 DM patients and 37 normal age-matched controls completed the study. Results showed that blood monocytes from type 2 DM patients had a significantly higher TLR4 but not TLR2 expression. Using a TLR4 ligand, lipopolysaccharide (LPS), to trigger TNF£\ production, a significantly higher TNF£\ production by blood leukocytes from type 2 DM patients than age-matched controls was found. The higher TNF£\ production by blood leukocytes from type 2 DM patients was associated with down-regulation of suppressor of cytokine signaling 1and 3 (SOCS-1 and SOCS-3) expression. We have further postulated that increase of oxidative stress or decrease of IFN-£\ production in type 2 DM patients was related to the alteration of TLR-4 response. Correction of SOCS-1 expression by addition of antioxidant, superoxide dismutase (SOD), but not IFN-£\, significantly decreased TNF£\ production in blood leukocytes from type 2 DM patients. This study is the first in the literature to identify an alteration of TLR4 expression associated with depressed SOCS-1 expression in leukocytes of type 2 DM patients. Results from this study highlight a potential pathway to improve chronic inflammation of type 2 DM patients via modulation of TLR4 expression and SOCS-1 mRNA expression of leukocytes.

A periodontite está relacionada à genética do hospedeiro, constituição do biofilme dental e fatores ambientais como o hábito de fumar. A metilação do DNA é um mecanismo de expressão genética que pode inibir ou silenciar a expressão do gene. Desta forma, vários pesquisadores têm se dedicado a estudar a influência genética sobre a suscetibilidade e/ou risco aumentado à doença periodontal. Estudos têm relatado associação entre vários biomarcadores epigenéticos com a inflamação periodontal. Considerando a hipótese de que existe associação do tabagismo com a metilação em genes relacionados à doença periodontal, o objetivo deste estudo foi verificar o padrão de metilação do DNA em células do epitélio oral de pacientes com periodontite crônica (CP) no promotor de um gene específico envolvido no controle da inflamação, como supressor da sinalização de citocinas (SOCS-1) em pacientes fumantes e não fumantes. O gene SOCS-1 é localizado no cromossomo 16p13.3, compostos por uma região amino-terminal, um domínio SH2 central e uma caixa SOCS. É um regulador negativo da via JAK / STAT. Inibe os efeitos biológicos de várias citocinas, incluindo IL-2, IL-3, IL-4, IL-6, interferão (INF) - γ e INF- α / β. Este foi um estudo caso-controle, comparando dois grupos, um grupo (teste) com consumo de 10 cigarros mínimos por dia, com diagnóstico de periodontite crônica e outro grupo controle que foram pacientes não fumantes com periodontite crônica. Para tal, DNA genômico foi purificado de células epiteliais bucais obtidas por meio de enxágue com sacarose 3%, por tempo único de coleta. O DNA foi modificado pelo bissulfito de Sódio e os padrões de metilação do DNA foram analisados com a técnica MS-PCR (Polymerase chain reaction). A análise estatística foi realizada pela plataforma estatística R version 3.3.2 Core Team (2016). Foi realizado Teste t de Student para amostras independentes e teste não paramétrico de Wilcoxon & Mann-Whitney para variáveis qualitativas; teste qui-quadrado e para a variável metilação, foi feito um teste exato de Fisher para testar a associação entre os grupos e a metilação. Os resultados indicaram que, para células epiteliais da mucosa bucal, a frequência de desmetilação no gene SOCS-1 é maior no grupo sem o hábito do fumo, em comparação ao grupo fumante. Foram detectadas diferenças no padrão de metilação entre os dois grupos. Ao estabelecer uma estimativa de risco relativo entre os grupos e a variável metilação, foi observado que pacientes fumantes têm 7,08 vezes (risco relativo) com um intervalo (1,95-51.46) de apresentar doença periodontal crônica, com um padrão de metilação no gene SOCS-1 / Periodontitis is related to host genetics, constitution of the dental biofilm and environmental factors such as smoking. DNA methylation is a mechanism of genetic expression that can inhibit or silence gene expression. In this way several researchers have been dedicated to study the genetic influence on the susceptibility and / or increased risk to periodontal disease. Studies have reported association between several epigenetic biomarkers with periodontal inflammation. Considering the hypothesis that there is an association between smoking and methylation in genes related to periodontal disease, the objective of this study was to verify the DNA methylation pattern in oral epithelial cells of patients with chronic periodontitis (ChP) in the promoter of a specific gene involved in the control of inflammation, as suppressor of cytokine signaling (SOCS-1) in smokers and nonsmokers patients. The SOCS-1 gene is located on chromosome 16p13.3 composed of an amino-terminal region, a central SH2 domain and a SOCS box. It is a negative regulator of the JAK / STAT path. It inhibits the biological effects of various cytokines, including IL-2, IL-3, IL-4, IL-6, interferon (INF) -γ and INF-α / β . This was an case-control type study, comparing two groups, a group with consumption of 10 minimum cigarettes per day, with a diagnosis of chronic periodontitis and another control group were non-smokers with chronic periodontitis. For this, genomic DNA was purified from oral epithelial cells obtained by rinsing with 3% sucrose, for a single time of collection. The DNA was modified by Sodium bisulfite and the methylation patterns of the DNA were analyzed with the MS-PCR technique (Polymerase chain reaction). Statistical analysis was performed by the statistical platform R version 3.3.2 Core Team (2016), Student\'s t-test was performed for independent samples and Wilcoxon\'s & Mann-Whitney non-parametric test for qualitative variables; chi-square test. For the methylation variable, an exact Fisher\'s test was performed to test the association between the groups and the methylation. The results indicated that, for oral mucosal epithelial cells, the frequency of demethylation in the SOCS-1 gene is higher in the non-smoking group as compared to the smoker group. statistically significant differences were detected in the methylation pattern between the two groups. When establishing an relative risk between the groups and the methylation variable, it was observed that smokers are 7.08 times (relative risk) of having chronic periodontal disease with a methylation pattern in the SOCS-1 gene

Made available in DSpace on 2015-07-22T20:49:56Z (GMT). No. of bitstreams: 0 Previous issue date: 2010-08-25 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / O melanoma é um tumor de origem neuroectodérmica resultante da proliferação e transformação maligna dos melanócitos, os quais se originam de precursores da crista neural que então migram para a pele e folículos capilares durante o processo de embriogênese, e se apresentam como células especializadas que produzem melanina, encontradas na camada basal da epiderme e nos folículos do cabelo onde sua homeostase é regulada pelos queratinócitos da epiderme. A última década assistiu a grandes avanços em aspectos celulares e moleculares do melanoma. As implicações terapêuticas contribuíram para o entendimento das vias de regulação nas células tumorais que resultam de complexas alterações em múltiplas cascatas de sinalização, controlando a mobilidade, controle do crescimento, invasão, metabolismo, liberação de citocinas e capacidade de escapar da resposta imune. No presente trabalho, o silenciamento com shRNAi de uma proteína reguladora da via de sinalização JAK / STAT denominada SOCS- 1 foi capaz de reverter o fenótipo tumorigênico das linhagens de melanoma murino B16F10-Nex2 inibindo a progressão e desenvolvimento tumoral e assim, um novo marcador crítico do melanoma metastático pode ser estudado de maneira isolada. Nos ensaios in vitro o silenciamento de SOCS-1 inibiu o crescimento e regulação do ciclo celular, motilidade e a invasão de Matrigel pelas células de melanoma. O ensaio clonogênico demonstrou a participação de SOCS-1 como um modulador de resistência ao anoikis. Além disso, o silenciamento de SOCS-1 culminou na redução da expressão de receptores tais como receptor do fator de crescimento endotelial (EGF), receptor de insulina e fator de crescimento fibroblástico (FGF). Nos ensaios in vivo o silenciamento de SOCS-1 inibiu o crescimento tumoral e metastático. Coletivamente, estes dados sugerem que o silenciamento da expressão da proteína SOCS-1 em células de melanoma é um evento crítico, levando a um perfil não tumorigênico. O silenciamento da expressão de SOCS-1 é uma abordagem nova e promissora para aumentar os alvos terapêuticos e assim prevenir o desenvolvimento e a progressão do melanoma. / Melanoma is the most aggressive form of skin cancer and its incidence has increased dramatically over the years. The origin of melanoma is neuroectodermal and it results from the proliferation and malignant transformation of melanocytes that originate from the neural crest and migrate to the skin and hair follicles during embryogenesis. The last decade has seen major advances in both cellular and molecular aspects of melanoma biology and therapeutic implications. Knowledge on the regulatory pathways involved in melanoma development and progression has advanced significantly in recent years. It is now recognized that melanoma development is regulated by multiple cascade signaling pathways that affect, motility, growth control, invasion, metabolism, cytokine release and the ability to escape immune response. Here, we demonstrate a novel signaling mechanism whereby silencing of SOCS-1 protein, a negative regulator of Jak/Stat pathway, leads to partial reversion of the tumorigenic phenotype of B16F10-Nex2 melanoma cells. SOCS-1 silencing with small hairpin RNA inhibits in vitro growth by cell cycle regulation and S phase arrest, motility inhibition and decreased melanoma cell invasion through Matrigel. Clonogenic assay showed that SOCS-1 acted as a modulator of anoikis resistance. Additionally, downregulation of SOCS-1 expression decreased the expression of epidermal growth factor (EGF), insulin receptor and fibroblast growth factor receptor (FGFR). We further demonstrate by in vivo assay that SOCS-1 silencing inhibits tumor growth and metastatic spread in the lungs. Collectively, these data show that silencing of SOCS-1 protein expression in melanoma cells is a critical event, leading to nontumorigenesis and incapacity to metastasize. / TEDE / BV UNIFESP: Teses e dissertações

HCV infection is associated with immune dysregulation and B cell Non-Hodgkins lymphoma (HCV-NHL). We have previously shown in vitro that HCV core protein differentially regulates T and B cell functions through two negative signaling pathways, programmed death-1 (PD-1) and suppressor of cytokine signaling-1 (SOCS-1). In this report, we performed a detailed immunologic analysis of T and B cell functions in the setting of HCV-NHL. We observed that T cells isolated from patients with HCV-NHL exhibited an exhausted phenotype including decreased expression of viral-specific and non-specific activation markers; whereas B cells exhibited an activated phenotype including over-expression of cell activation markers and immunoglobulins compared to healthy subjects. Individuals with HCV alone or NHL alone exhibited abnormal T and B cell phenotypes, but to a lesser extent compared to HCV-NHL. This differential activation of T and B lymphocytes was inversely associated with the expression of PD-1 and SOCS-1. Interestingly, blocking PD-1 during TCR activation inhibited SOCS-1 gene expression, suggesting that these regulatory pathways are linked in T cells. Importantly, blocking PD-1 also restored the impaired T cell functions observed in the setting of HCV-NHL. These results support a coordinated mechanism by which HCV might cause immune dysregulation that is associated to HCV-NHL.

No description available.

No description available.

Les cytokines jouent un rôle fondamental dans la régulation des processus biologiques via la cascade de signalisation JAK-STAT. Les « Suppressors of Cytokine Signalling » (SOCS), protéines intracellulaires, inhibent la voie JAK-STAT. Plusieurs études supportent leur implication dans des maladies immunitaires, mais peu d’informations sont disponibles sur leur expression par les lymphocytes T humains. Nous postulons que les cytokines Interféron-β(IFN-β) et Interleukine-27 (IL-27), dotées d’un potentiel immuno-régulateur, ont des rôles bénéfiques via l’induction des SOCS. L’impact de l’IFN-β et l’IL-27 sur l’expression des SOCS-1 et SOCS-3 par des cellules T CD8 et CD4 humaines a été étudié en utilisant des cellules sanguines de donneurs sains. L’expression de ces régulateurs a été évaluée aux niveaux de l’ARNm par qRT-PCR et protéique par immunocytochimie. Les SOCS-1 et SOCS-3 ont été rapidement induits en ARNm dans les deux types cellulaires en réponse à l’IFN-β ou l’IL-27 et une augmentation de l’expression a été confirmée au niveau protéique. Afin de mimer les thérapies à base d’IFN-β, les cellules T ont été exposées chroniquement à l’IFN-β. Après chaque ajout de cytokine les cellules T ont augmenté l’expression du SOCS-1, sans moduler le SOCS-3. L’IL-27 a induit les SOCS-1 et SOCS-3 préférentiellement dans les cellules T CD8 ; ceci corrèle avec des résultats du laboratoire démontrant une plus petite expression des récepteurs à l’IL-27 par les lymphocytes T CD4 que les CD8. Notre projet a permis d’élucider l’expression des SOCS dans deux populations de cellules T et de clarifier les mécanismes d’actions de l’IFN-β et l’IL-27. / Cytokines regulate fundamental biological processes via the JAK-STAT signaling pathway. Suppressors of Cytokine Signaling proteins (SOCS), intracellular proteins, inhibit the JAK-STAT pathway. Emerging evidence supports the involvement of SOCS in diseases of the immune system but no data is available regarding their expression in human T cells. We postulate that the cytokines Interferon-β (IFN-β) and Interleukin-27 (IL-27), both potential immuno-regulators, have beneficial roles through the induction of SOCS proteins. The impact of IFN-β and IL-27 on the SOCS-1 and SOCS-3 expression by human CD4 and CD8 T cells was assessed using peripheral blood mononuclear cells from healthy donors. We evaluated the expression of SOCS-1 and SOCS-3 at the mRNA level by qRTPCR and at the protein level by immunocytochemistry. A rapid increase of SOCS-1 and SOCS-3 mRNA levels was observed upon cytokine addition, and such upregulation was confirmed at the protein level. To mimic patients under IFN-β treatment, both T cell subsets were chronically exposed to IFN-β. We observed an increase of SOCS-1 after each stimulation but not for SOCS-3. IL-27 stimulation increased SOCS-1 and SOCS-3 mRNA levels in CD8 T cells but only slightly in CD4 T cells; these observations correlate with previous observations in our laboratory showing less IL-27 receptors on CD4 T cells than CD8 counterparts. Our project determined the distinct expression of SOCS proteins in different human T cells subsets. This study could highlight the mechanism of action of cytokines such as IFN-β and IL-27.

Les cytokines jouent un rôle fondamental dans la régulation des processus biologiques via la cascade de signalisation JAK-STAT. Les « Suppressors of Cytokine Signalling » (SOCS), protéines intracellulaires, inhibent la voie JAK-STAT. Plusieurs études supportent leur implication dans des maladies immunitaires, mais peu d’informations sont disponibles sur leur expression par les lymphocytes T humains. Nous postulons que les cytokines Interféron-β(IFN-β) et Interleukine-27 (IL-27), dotées d’un potentiel immuno-régulateur, ont des rôles bénéfiques via l’induction des SOCS. L’impact de l’IFN-β et l’IL-27 sur l’expression des SOCS-1 et SOCS-3 par des cellules T CD8 et CD4 humaines a été étudié en utilisant des cellules sanguines de donneurs sains. L’expression de ces régulateurs a été évaluée aux niveaux de l’ARNm par qRT-PCR et protéique par immunocytochimie. Les SOCS-1 et SOCS-3 ont été rapidement induits en ARNm dans les deux types cellulaires en réponse à l’IFN-β ou l’IL-27 et une augmentation de l’expression a été confirmée au niveau protéique. Afin de mimer les thérapies à base d’IFN-β, les cellules T ont été exposées chroniquement à l’IFN-β. Après chaque ajout de cytokine les cellules T ont augmenté l’expression du SOCS-1, sans moduler le SOCS-3. L’IL-27 a induit les SOCS-1 et SOCS-3 préférentiellement dans les cellules T CD8 ; ceci corrèle avec des résultats du laboratoire démontrant une plus petite expression des récepteurs à l’IL-27 par les lymphocytes T CD4 que les CD8. Notre projet a permis d’élucider l’expression des SOCS dans deux populations de cellules T et de clarifier les mécanismes d’actions de l’IFN-β et l’IL-27. / Cytokines regulate fundamental biological processes via the JAK-STAT signaling pathway. Suppressors of Cytokine Signaling proteins (SOCS), intracellular proteins, inhibit the JAK-STAT pathway. Emerging evidence supports the involvement of SOCS in diseases of the immune system but no data is available regarding their expression in human T cells. We postulate that the cytokines Interferon-β (IFN-β) and Interleukin-27 (IL-27), both potential immuno-regulators, have beneficial roles through the induction of SOCS proteins. The impact of IFN-β and IL-27 on the SOCS-1 and SOCS-3 expression by human CD4 and CD8 T cells was assessed using peripheral blood mononuclear cells from healthy donors. We evaluated the expression of SOCS-1 and SOCS-3 at the mRNA level by qRTPCR and at the protein level by immunocytochemistry. A rapid increase of SOCS-1 and SOCS-3 mRNA levels was observed upon cytokine addition, and such upregulation was confirmed at the protein level. To mimic patients under IFN-β treatment, both T cell subsets were chronically exposed to IFN-β. We observed an increase of SOCS-1 after each stimulation but not for SOCS-3. IL-27 stimulation increased SOCS-1 and SOCS-3 mRNA levels in CD8 T cells but only slightly in CD4 T cells; these observations correlate with previous observations in our laboratory showing less IL-27 receptors on CD4 T cells than CD8 counterparts. Our project determined the distinct expression of SOCS proteins in different human T cells subsets. This study could highlight the mechanism of action of cytokines such as IFN-β and IL-27.

La protéine SOCS-1 (Suppressor Of Cytokine Signalling 1) a été historiquement caractérisée comme un régulateur négatif de la voie de signalisation JAK/STAT. Cette dernière, activée en réponse à de nombreuses cytokines, hormones et facteurs de croissance, aboutit à l'expression de nombreux gènes cibles, dont le gène codant pour la protéine SOCS-1. Dans un premier travail, nous avons étudié la régulation du gène Socs-1 après une stimulation par l'interféron-gamma. Nous avons ainsi mis en évidence l'implication des facteurs de transcription IRF-1 et Sp2 dans la régulation transcriptionnelle du gène Socs-1. Dans de nombreuses tumeurs humaines, l'expression du gène Socs-1 est inhibée par méthylation aberrante de l'ADN. Dans la lignée cellulaire métastatique colique, SW620, la réexpression de la protéine SOCS-1 provoque une inhibition des caractères invasifs. Cette transformation du phénotype cellulaire s'accompagne d'une réexpression de la E-cadherine à la membrane.

Chronic hepatitis C virus (HCV) infection is associated with cirrhosis, autoimmunity and lymphoproliferative disorders. We have previously reported a differential regulation of T and B lymphocytes by HCV core protein in vitro. In this report, we employed a translational approach to characterize the activation status of peripheral B cells from individuals with chronic HCV infection and to explore potential mechanisms for B-cell dysregulation in the setting of HCV infection. In contrast to the T-cell suppression observed in HCV-infected individuals, B cells exhibit a non-specific polyclonal activation phenotype, characterized by significantly higher levels of (1) the early activation marker, CD69, (2) the costimulatory molecule, CD86, and (3) the CCR5 chemokine receptor, CD195, when compared with B cells from healthy donors in response to phytohaemagglutinin (PHA) stimulation. Importantly, tumour necrosis factor- and Apo-L-related leucocyte-expressed ligand-1 (TALL-1), also known as B-lymphocyte stimulator (BLYS), was found to be up-regulated on the surface of B cells from HCV patients in response to PHA as well as HCV core antigen stimulation. This up-regulation of TALL-1 was associated with vigorous memory B-cell responses to viral antigenic stimulation. Additionally, suppressor of cytokine signalling-1 (SOCS-1), a negative feedback immunoregulator that is inhibited in B lymphocytes by HCV core in vitro, was also inhibited in B cells from HCV patients when compared with healthy donors. These findings suggest that TALL-1 over-expression and SOCS-1 suppression are associated with aberrant B-cell activation, providing a plausible basis for the B-cell clonal expansion underlying the lymphoproliferative disorders and autoimmune phenomena observed during chronic HCV infection.